pharma · Glaucoma · Macular Edema
Allergan Pharmaceuticals International
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Glaucoma, Macular Edema, Macular Degeneration, Dry Eye Syndromes, Choroid Neovasculariz
Dublin, IE HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, IE
- Programs
- 13
- Drugs
- 15
- Patents
- 25
AGN-195263
Phase 3 · small molecule · Dry Eye Syndromes
AGN-195263 for Dry Eye Syndromes is a Phase 3 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).
Internal code 195263-010
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Allergan Pharmaceuticals International Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Dry Eye Syndromes
- Status
- terminated
- Trials
- 1